This study evaluated effectiveness of SEC in PsA prevention of a subgroup of pts from SELENA: PsO pts w/o PsA & nail dse (n=292) At 5 yrs: 🎯98.3% didn't develop PsA (yEAIR 0.49) 🎯 Sustained PASI, PGA 0/1 💡Longterm SEC effective for PsA prevention? #ACR25 @RheumNow Abs1463 https://t.co/t7P1Oerbrw

12 year follow up radiographic data in axial SpA - ASAS definition of early stage does not significantly influence long term radiographic outcomes. Abt#1432 #ACR25 @RheumNow https://t.co/fFP2CW6X0B

Survival outcomes in patients with axial SpA and concomitant cancer are the same as those without. #abst1429 #ACR25 @RheumNow https://t.co/wicN3s9JrR

Sun et al. Telitacicept in SARD-ILD (pSS, ASS, RA). 25 patients. Improvements in CT, PFTs, 6MWT. @RheumNow #ACR25 Abstr#1361 https://t.co/q679LOaOyL

Short chain fatty acids (SCFA) and the relevant microbiome have been linked to RA development and severity. Study of monozygotic twins, where only one has RA, two diff cohorts: lower SCFA lower SCFA microbiome Biomarkers, or even therapeutic target? #ACR25 ABST0442 @RheumNow https://t.co/HW1YfkfOG3

Classification of sacrioilitis using new york criteria vs a convolutional neural network. Abst#1421 #acr25 @RheumNow Yes no results - accuracy was 70 percent. But the exact grade was right 22 percent times only! https://t.co/9o8OGesH0n

Global survey from the 2024 Adelphi Lupus Dse Specific Programme evaluated pt burden & MD/Pt Tx preferences: Efficacy & safety - top 2 MD-reported reasons for tx initiation OD, oral dosing-most preferred mode by MD & Pts Shared decision-making is key #ACR25 @RheumNow Abs1551 https://t.co/rmpCATCa78

In pooled analysis of 9 PsA trials, 6.9% of secukinumab-treated patients had fungal infections, mostly mild/moderate. Candida rates were low (1.86–2.18/100 PY) and didn’t increase over time. 89.7% resolved fully; only 0.8% led to discontinuation. Abstract 1459 @RheumNow #ACR25 https://t.co/kltMZVEDf9

Screening for ILD in RA patients: CXR and PFTs by themselves are close to a waste of time. When it comes to screening (high-risk) RA patients, it’s HRCT (or lung USS) or nothing really. (in keeping with EULAR, ACR guidelines) #ACR25 ABST1335 @RheumNow https://t.co/XBDxLwYsAT

England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta

This poster is absolutely bonkers & I LOVE it Huge table. Frequency of everything over time Really interesting to see which activity persists / how much damage is accumulated Every trial should be obligated to share this (esp SLE!) #ACR25 @RheumNow #ACRBest Abst#1608 https://t.co/blRrvwi3qP

Mease et al. What agent to use after failure of first TNFi in PsA. Real world study, 320 patients. Switching to upadacitinib led to better joint responses than second TNFi or IL17i @RheumNow #ACR25 Abstr#1453 https://t.co/SQnN0skw7r

Interim analysis of Ph3 TULIP-SC trial: Anifrolumab 120mg SC or PBO weekly + SOC x 52wks Primary endpt met: BICLA response w/Anifrolumab (60.3%) vs. PBO(43.9%)[p=0.014] Pts on Ani had sustained BICLA response upto wk 52 (HR 2.1) Promising results. #ACR25 @RheumNow Abs1545 https://t.co/nqse1BiGq2

What can we use to better predict MACE in RA patients? ESPOIR cohort showed value of two cardiac biomarkers: - hs-cTnT - soluble ST2 Combined, predicted MACE even after adjusting for disease activity/traditional CV RF. We need something like this! #ACR25 ABST1334 @RheumNow https://t.co/EUNDuuMaYD